Ocular Therapeutix, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ocular Therapeutix, Inc.
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
A mega deal with Eli Lilly to exclusively market, promote and distribute Emgality (galcanezumab) in China for migraine prevention offers a critical opportunity for C-Bridge backed AffaMed in an untapped, large market, CFO Vijay Karwal told Scrip in an exclusive video interview on the sidelines of EBD's Asia Bio Partnering Forum.
The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
- Controlled Release
- Drug Delivery
- Implantable Devices
Surgical Equipment & Devices
- Surgical Sealants
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.